2017
DOI: 10.1002/ijc.31153
|View full text |Cite|
|
Sign up to set email alerts
|

An ERCC4 regulatory variant predicts grade‐3 or ‐4 toxicities in patients with advanced non‐small cell lung cancer treated by platinum‐based therapy

Abstract: Platinum-based chemotherapy (PBC) in combination with the 3 generation drugs is the first-line treatment for patients with advanced non-small cell lung cancer (NSCLC); however, the efficacy is severely hampered by grade 3-4 toxicities. Nucleotide excision repair (NER) pathway is the main mechanism of removing platinum-induced DNA adducts that contribute to the toxicity and outcome of PBC. We analyzed data from 710 Chinese NSCLC patients treated with PBC and assessed the associations of 25 potentially functiona… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 31 publications
(55 reference statements)
0
4
0
Order By: Relevance
“…XPF, located on chromosome 16p13.12, is also another important protein in the NER pathway, which plays a key role in DNA repair and maintenance of chromosome stability [27]. XPF polymorphisms can alter the function of XPF , leading to tumorigenesis and affecting the outcome of cisplatin-based chemotherapy [28]. Previously, XPF variants were reported to be associated with various tumors, including colorectal, ovarian, and lung cancer [29-31].…”
Section: Discussionmentioning
confidence: 99%
“…XPF, located on chromosome 16p13.12, is also another important protein in the NER pathway, which plays a key role in DNA repair and maintenance of chromosome stability [27]. XPF polymorphisms can alter the function of XPF , leading to tumorigenesis and affecting the outcome of cisplatin-based chemotherapy [28]. Previously, XPF variants were reported to be associated with various tumors, including colorectal, ovarian, and lung cancer [29-31].…”
Section: Discussionmentioning
confidence: 99%
“…And there were missense mutations located in 6 tumor susceptibility genes, including PTCH1, BRCA2, BLM, ERCC4, BRCA1, and SETBP1 (Table S7), whose function loss have been closely associated with several hereditary tumor susceptibility syndromes (Acuna-Hidalgo et al, 2017;Qian et al, 2017;Romagnolo, Romagnolo & Selmin, 2015;Zhang et al, 2018). Interestingly, BRCA1 and BRCA2 are key members participating in homologous recombination (HR) repair upon DNA damage and the missense mutations were likely to affect the HR repair potential.…”
Section: Pcb153 Poisoning Induced Missense Mutations Of 6 Tumor Suppressor Genesmentioning
confidence: 99%
“…Driver mutations in codons 12,13,59,61,117,and 146 of KRAS and NRAS genes,and the mutation in codon 600 of BRAF gene (Sepulveda et al, 2017) in patient samples were analyzed by FastTarget next-generation sequencing (Zhang et al, 2018).…”
Section: Screening For Tumor Microsatellite Instability and Kras Nras And Braf Oncogene Mutationsmentioning
confidence: 99%